User menu

Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.

Bibliographic reference Patteet , Lisbeth ; Haufroid, Vincent ; Maudens , Kristof ; Sabbe , Bernard ; Morrens , Manuel ; et. al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.. In: European Journal of Clinical Pharmacology, Vol. 72, no.2, p. 175-184 (2016)
Permanent URL http://hdl.handle.net/2078.1/184523
  1. Hiemke C., Baumann P., Bergemann N., Conca A., Dietmaier O., Egberts K., Fric M., Gerlach M., Greiner C., Gründer G., Haen E., Havemann-Reinecke U., Jaquenoud Sirot E., Kirchherr H., Laux G., Lutz U., Messer T., Müller M., Pfuhlmann B., Rambeck B., Riederer P., Schoppek B., Stingl J., Uhr M., Ulrich S., Waschgler R., Zernig G., AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011, 10.1055/s-0031-1286287
  2. Haufroid Vincent, Hantson Philippe, CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants, 10.3109/15563650.2015.1049355
  3. nomenclature CDa (Last accessed on June 2015) CYP2D6 Allele nomenclature. http://www.cypalleles.ki.se/cyp2d6.htm .
  4. Steimer Werner, Pharmacogenetics and Psychoactive Drug Therapy: Ready for the Patient? : , 10.1097/ftd.0b013e3181e1a78d
  5. Ingelman-Sundberg Magnus, Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future, 10.1016/j.tips.2004.02.007
  6. Antunes Marina Venzon, de Oliveira Vanessa, Raymundo Suziane, Staudt Dilana Elisabeth, Gössling Gustavo, Biazús Jorge Villanova, Cavalheiro José Antônio, Rosa Daniela Dornelles, Mathy Geneviève, Wallemacq Pierre, Linden Rafael, Schwartsmann Gilberto, Haufroid Vincent, CYP3A4*22is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen, 10.2217/pgs.15.13
  7. Kirchheiner J, Nickchen K, Bauer M, Wong M-L, Licinio J, Roots I, Brockmöller J, Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, 10.1038/sj.mp.4001494
  8. Luo Huai-Rong, Gaedigk Andrea, Aloumanis Vasileios, Wan Yu-Jui Yvonne, Identification of CYP2D6 impaired functional alleles in Mexican Americans, 10.1007/s00228-005-0044-4
  9. BROCKMOLLER J, KIRCHHEINER J, SCHMIDER J, WALTER S, SACHSE C, MULLEROERLINGHAUSEN B, ROOTS I, The impact of the polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment, 10.1067/mcp.2002.127494
  10. van Schaick RHN, Grandia L, de Goede A, Bet PM, Bekers O, Guchelaar HJ, Goldschmidt HMJ, Meijer MMC, Mulder H, van Der Weide J, Deneer VHM (2008) Nederlandse consensus: CYP2D6 genotype '1-0' ingedeeld als intermediaire metaboliseerder. Ned Tijdschr Klin Chem Labgeneesk 33:52–53
  11. Shin Jae-Gook, Kane Khadidjatou, Flockhart David A., Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol : Inhibition of CYP2D6 by haloperidol metabolites, 10.1046/j.1365-2125.2001.01313.x
  12. Kudo Shoji, Ishizaki Takashi, Pharmacokinetics of Haloperidol : An Update, 10.2165/00003088-199937060-00001
  13. Patteet Lisbeth, Maudens Kristof E., Sabbe Bernard, Morrens Manuel, De Doncker Mireille, Neels Hugo, High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography–tandem mass spectrometry, 10.1016/j.cca.2013.11.024
  14. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS, The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype, 10.1038/sj.clpt.6100406
  15. Borges Silvana, Desta Zeruesenay, Jin Yan, Faouzi Azzouz, Robarge Jason D., Philip Santosh, Nguyen Anne, Stearns Vered, Hayes Daniel, Rae James M., Skaar Todd C., Flockhart David A., Li Lang, Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients, 10.1177/0091270009359182
  16. Crews K R, Gaedigk A, Dunnenberger H M, Klein T E, Shen D D, Callaghan J T, Kharasch E D, Skaar T C, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype, 10.1038/clpt.2011.287
  17. Hendset Magnhild, Hermann Monica, Lunde Hilde, Refsum Helge, Molden Espen, Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole, 10.1007/s00228-007-0373-6
  18. Spina Edoardo, de Leon Jose, Clinical applications of CYP genotyping in psychiatry, 10.1007/s00702-014-1300-5
  19. Swen J J, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A H, Mulder H, Rongen G A P J M, van Schaik R H N, Schalekamp T, Touw D J, van der Weide J, Wilffert B, Deneer V H M, Guchelaar H-J, Pharmacogenetics: From Bench to Byte— An Update of Guidelines, 10.1038/clpt.2011.34
  20. Samer C. F., Lorenzini K. Ing, Rollason V., Daali Y., Desmeules J. A., Applications of CYP450 Testing in the Clinical Setting, 10.1007/s40291-013-0028-5
  21. Tyndale RF, Kalow W., Inaba T., Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase)., 10.1111/j.1365-2125.1991.tb05588.x
  22. Pan L., Belpaire F. M., In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol, 10.1007/s002280050679
  23. van der Weide Karen, van der Weide Jan, The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients : , 10.1097/jcp.0000000000000319
  24. Patteet Lisbeth, Morrens Manuel, Maudens Kristof E., Niemegeers Peter, Sabbe Bernard, Neels Hugo, Therapeutic Drug Monitoring of Common Antipsychotics : , 10.1097/ftd.0b013e3182708ec5.
  25. Aravagiri Manickam, Marder Stephen R., Van Putten Theodore, Marshall Barringer D., Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol, 10.1016/0378-4347(94)00134-0
  26. Pan Liping, Rosseel Marie T., Belpaire Frans M., Comparison of Two High-Performance Liquid Chromatographic Methods for Monitoring Plasma Concentrations of Haloperidol and Reduced Haloperidol : , 10.1097/00007691-199804000-00015
  27. Murray Michael, Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents, 10.1211/jpp.58.7.0001
  28. Hendset Magnhild, Molden Espen, Refsum Helge, Hermann Monica, Impact of CYP2D6 Genotype on Steady-State Serum Concentrations of Risperidone and 9-Hydroxyrisperidone in Patients Using Long-Acting Injectable Risperidone : , 10.1097/jcp.0b013e3181c17df0
  29. Gunes Arzu, Spina Edoardo, Dahl Marja-Liisa, Scordo Maria Gabriella, ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety : , 10.1097/ftd.0b013e3181858ca9
  30. de Leon Jose, Susce Margaret T., Pan Run-Mei, Fairchild Maureen, Koch Walter H., Wedlund Peter J., The CYP2D6 Poor Metabolizer Phenotype May Be Associated With Risperidone Adverse Drug Reactions and Discontinuation, 10.4088/jcp.v66n0103
  31. Linnet Kristian, Wiborg Ove, Influence of Cyp2D6 Genetic Polymorphism on Ratios of Steady-state Serum Concentration to Dose of the Neuroleptic Zuclopenthixol : , 10.1097/00007691-199612000-00001
  32. Jerling Markus, Dahl Marja-Liisa, Åberg-Wistedt Anna, Liljenberg Bo, Landell Nils-Erik, Bertilsson Leif, Sjöqvist Folke, The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol*, 10.1016/s0009-9236(96)90111-3
  33. Jaanson Peeter, Marandi Toomas, Kiivet Raul-Allan, Vasar Veiko, Vään Siiri, Svensson Jan-Olof, Dahl Marja-Liisa, Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype, 10.1007/s00213-002-1059-5